September 2025: The biggest biotech funding rounds of the month
This issue of our newsletter is supported by Altasciences.
In September 2025, public companies led the way as uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds from public offerings, with uniQure’s $345 million raise being the largest of the month.
Indeed, last month proved to be another very strong month for public biotech fundraising in general, where for the third time this year, it outperformed private biotech fundraising over the course of the month. Additionally, public biotech fundraising also achieved its second largest total of the year so far, as $2.442 billion was raised.
To find out more, read the full article: “The biggest biotech funding rounds in September 2025”
A MESSAGE FROM OUR SPONSOR ALTASCIENCES
Accelerate early-phase clinical trials by up to six weeks
Conducting early-phase clinical trials in Canada can accelerate development timelines by up to six weeks while reducing costs and administrative burden. With predictable regulatory reviews and high-quality standards, Canadian studies support EU and UK approvals, helping sponsors move faster and make critical go/no-go decisions in a competitive market.
Want to advertise with us? Become our next sponsor.
🔥 More noteworthy articles from this week:
The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision to back out of its $1 billion expansion was unexpected, with many calling it a blow for the region. However, others believe that this has been a long time coming, as life science investments in the U.K. have been scarce and spending has declined.
Complex regional pain syndrome (CRPS) is a rare but severe neuropathic pain condition that causes intense, long-lasting pain, often following an injury or surgery. Patients frequently report some of the highest pain scores recorded in clinical practice, yet there is still no approved therapy. AKIGAI, a Norway-based company, is hoping to change the narrative in neuropathic pain with EGFR inhibitors.
As mRNA technology evolves to prevent other infectious diseases, treat cancers and genetic disorders, more biotech companies have entered the field in recent times. Here are six mRNA companies that have recently raised funds to push their candidates into preclinical and clinical trials.
Coming out of the lull of August, the biopharma industry witnessed four billion-dollar acquisition deals in September 2025. Licensing deals involved antibody-drug conjugates, small molecules, and RNAs, with Novartis taking the cake for the highest number of collaborations. New players also forged relationships to develop new therapies.
On this episode of Beyond Biotech, Dylan Kissane spoke with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. They discussed the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done.
Join Inpart’s upcoming webinar on October 22nd (4pm CET / 10am EDT) with Novo Nordisk experts Jannie Fuhlendorff and Daniel Goday Sagarra. Discover best practices, digital tools, and the balance of human relations and technology driving world-leading Alliance Management. Save your seat!
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.